<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427712</url>
  </required_header>
  <id_info>
    <org_study_id>P12-893</org_study_id>
    <nct_id>NCT01427712</nct_id>
  </id_info>
  <brief_title>Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis</brief_title>
  <official_title>Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at collecting the information related to the safety and effectiveness in the
      pancreatic exocrine insufficiency patients due to cystic fibrosis receiving the treatment
      with LipaCreon in order to evaluate the effective and safe use of LipaCreon.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse drug reaction</measure>
    <time_frame>Once a year until end of Follow-up period up to 7 years</time_frame>
    <description>Number of participants who reported adverse drug reaction. Name of adverse event, Seriousness, Outcome, Causal relation to LipaCreon.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>At week 52</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall improvement rating</measure>
    <time_frame>At week 24</time_frame>
    <description>4 grades: Effective, unchanged, aggravation, unassessable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall improvement rating</measure>
    <time_frame>At week 52</time_frame>
    <description>4 grades: Effective, unchanged, aggravation, unassessable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>Baseline</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>At week 4</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>At week 8</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>At week 12</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>At week 24</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>2nd year</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>3rd year</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>4th year</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>5th year</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>6th year</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition assessment items</measure>
    <time_frame>7th year</time_frame>
    <description>Body Mass Index, Serum total protein, Albumin, Total cholesterol, Triglyceride, Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>Baseline</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>At week 4</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>At week 12</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>At week 8</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>At week 52</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>At week 24</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>3rd year</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>2nd year</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>5th year</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>4th year</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>7th year</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms relating to pancreatic exocrine insufficiency</measure>
    <time_frame>6th year</time_frame>
    <description>Steatorrhea, Frequency of defecation, Diarrhea, Bad odor of feces, Appetite loss, Abdominal distention</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Exocrine Pancreatic Insufficiency</condition>
  <condition>Pancreatic Diseases</condition>
  <condition>Digestive System Diseases</condition>
  <arm_group>
    <arm_group_label>LipaCreon</arm_group_label>
    <description>those with an exposure</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who receive LipaCreon for the replacement of pancreatic digestive enzymes in
        pancreatic exocrine insufficiency
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients who receive LipaCreon for the replacement of pancreatic digestive enzymes in
             pancreatic exocrine insufficiency due to cystic fibrosis

        Exclusion Criteria

          -  Patients with a history of hypersensitivity to the ingredient of LipaCreon.

          -  Patients with a history of hypersensitivity to porcine protein
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Kato, MD., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Japan Co.,Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abbott Japan PMOS Desk</last_name>
    <phone>+81-3-4588-4621</phone>
    <email>ABTJ-PMOS@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Kato, MD., Ph.D.</last_name>
    <email>jun.kato@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 73813</name>
      <address>
        <city>Aichi</city>
        <zip>462-8508</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 73813</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator # 96698</name>
      <address>
        <city>Aichi</city>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000141</name>
      <address>
        <city>Aichi</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator no. ORG-000842</name>
      <address>
        <city>Aichi</city>
        <zip>470-0224</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator # 93736</name>
      <address>
        <city>Aichi</city>
        <zip>474-8710</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research facility ORG-000972</name>
      <address>
        <city>Ehime</city>
        <zip>794-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator # 93735</name>
      <address>
        <city>Ibaraki</city>
        <zip>305-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 88673</name>
      <address>
        <city>Ibaraki</city>
        <zip>305-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 65529</name>
      <address>
        <city>Ishikawa</city>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 65529</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 65530</name>
      <address>
        <city>Kagawa</city>
        <zip>760-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 65530</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 65527</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 65527</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 65528</name>
      <address>
        <city>Miyagi</city>
        <zip>980-0872</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 65528</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001138</name>
      <address>
        <city>Oita</city>
        <zip>874-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000594</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Research facility ORG-000971</name>
      <address>
        <city>Shizuoka</city>
        <zip>438-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site reference ID/Investigator# 117495</name>
      <address>
        <city>Tochigi</city>
        <zip>329-0431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research facility no. ORG-001309</name>
      <address>
        <city>Tokyo</city>
        <zip>108-8329</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67122</name>
      <address>
        <city>Tokyo</city>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 67122</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>August 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2011</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Gastrointestinal Agents</keyword>
  <keyword>Pancreatic Diseases</keyword>
  <keyword>Pancrelipase</keyword>
  <keyword>Exocrine Pancreatic Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

